Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GJB2 | P29033 | 2/20 | 0.48 |
| ▸ | NT5E | P21589 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.46 |
| ▸ | CDC25B | P30305 | 6/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.45 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.45 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.45 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.45 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.45 |
| ▸ | TACR2 | P21452 | 1/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.44 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13308240 | 0.90 | NT5E (0.48) | GJB2NT5EPTPN1CDC25BSLC6A2 | |
| SCHEMBL5466098 | 0.89 | GJB2 (0.56) | GJB2NT5EPTPN1CDC25BSLC6A2 | |
| SCHEMBL14414817 | 0.89 | GJB2 (0.56) | GJB2NT5EPTPN1CDC25BSLC6A2 | |
| SCHEMBL8221413 | 0.88 | NT5E (0.54) | GJB2NT5EPTPN1CDC25BSLC6A2 | |
| SCHEMBL10523689 | 0.88 | NT5E (0.54) | GJB2NT5EPTPN1CDC25BSLC6A2 | |
| SCHEMBL18744555 | 0.88 | NT5E (0.54) | GJB2NT5EPTPN1CDC25BSLC6A2 | |
| SCHEMBL977852 | 0.88 | NT5E (0.54) | GJB2NT5EPTPN1CDC25BSLC6A2 | |
| SCHEMBL10523693 | 0.88 | NT5E (0.54) | GJB2NT5EPTPN1CDC25BSLC6A2 | |
| SCHEMBL12136337 | 0.87 | PTPN1 (0.48) | GJB2NT5EPTPN1CDC25BSLC6A2 | |
| SCHEMBL19337558 | 0.87 | SLC6A2 (0.46) | GJB2NT5EPTPN1CDC25BSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624255-B2 | Carbohydrate-mediated tumor targeting | ARIZONA BOARD OF REGENTS (US) | 2017-04-18 | — | — | US | disclosed |
| US-20120148502-A1 | Carbohydrate-Mediated Tumor Targeting | Arizona Board of Regents, a body corporate of the State of Ariz. acting for and on behalf of Ariz. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120148502-A1 | Carbohydrate-Mediated Tumor Targeting | CA14, CA13, CA12 | GJB2 3860/4885NT5E 4198/4885PTPN1 3098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.